PDCD1 and pancreatic adenocarcinoma: It has also been shown that the oxidative metabolism of tumor cells is a barrier to PD‐1 immunotherapy, and that mitochondrial oxidative phosphorylation is not only not impaired but more activated in several cancers (pancreatic adenocarcinoma, melanoma, and leukemia).35